Hand Osteoarthritis
Conditions
Brief summary
Different types of pain may be present in patients with hand osteoarthritis, including nociceptive pain and non-nociceptive pain. This makes adequate pain treatment difficult, and thus new treatment options are needed. To this end, this trial will evaluate the effect of transcutaneous pulsed radiofrequency for the treatment of hand osteoarthritis pain.
Detailed description
In this randomized clinical trial, patients with hand osteoarthritis, recruited from the Leiden University Medical Center Rheumatology outpatient clinic, aged 18-80 and fulfilling hand pain criteria will be randomized to undergo trancutaneous pulsed radiofrequency therapy of the hand or a sham. The effect will be measured in change in 10 point numeric rating scale for pain in the hand over 6 weeks. This RCT will have little burdens and risk for the subjects. The proposed intervention, tPRF, is well tolerated, with no known serious side effects.
Interventions
single treatment with transcutaneous pulsed radiofrequency, for a duration of 15 minutes, at a strength of 800 mA.
DEVICESham
Sham treatment by turning on the device in demo mode. No treatment delivered, but indistinguishable by sound or visual signals or sensations felt by the study participant
Sponsors
Leiden University Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Age 18-80 * Hand osteoarthritis according to the ACR criteria * Hand pain of at least 30mm on a 100mm VAS * Chronic hand pain
Exclusion criteria
* Known inflammatory rheumatic diseases * Psoriasis * Seropositivity for rheumatoid factor of anti-CCP antibodies * No understanding of the Dutch language * Fibromyalgia (Following the ACR 2011 classification criteria) * Neurological disorders interfering with pain perception and measurements * Carpal tunnel syndrome interfering with pain perception and measurements * History of chemo- and/or radiotherapy * Spinal surgery or spinal trauma with lasting complaints interfering with pain perception and measurements * Cognitive impairment or psychiatric conditions interfering with pain perception and measurements * Pregnancy or breast-feeding * Eye surgery for glaucoma or keratoconus or other surgery of the cornea in the three preceding months * Presence of an implantable cardioverter-defibrillator (ICD), neurostimulator or pacemaker * Metal implants in the hand, arm, shoulder or neck of the side that is to be treated
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Hand pain at 6 weeks after trancutaneous pulsed radiofrequency or sham | 6 weeks | Hand pain measured in a 0-10 numeric rating scale after trancutaneous pulsed radiofrequency or sham |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Effect of transcutaneous pulsed radiofrequency therapy on central sensitization index scores | 6 weeks, 12 weeks | Effect of transcutaneous pulsed radiofrequency therapy on central sensitization index scores, range 0-100, with higher scores indicating more signs of central sensitization. |
| Effect of transcutaneous pulsed radiofrequency therapy on Michigan Hand Outcome Questionnaire | 6 weeks, 12 weeks | Effect of transcutaneous pulsed radiofrequency therapy on MHOQ scores, ranged 0-100 per domain, with higher scores indicating better oucomes. |
| Effect of transcutaneous pulsed radiofrequency therapy on AUSCAN pain scores | 6 weeks, 12 weeks | Effect of transcutaneous pulsed radiofrequency therapy on AUSCAN pain scores (Australian/Canadian Hand Osteoarthritis Index \[AUSCAN\] pain subscale, range 0-20, with higher scores indicating more pain) |
| Hand pain at 12 weeks after trancutaneous pulsed radiofrequency or sham | 12 weeks | Hand pain measured in a 0-10 numeric rating scale after trancutaneous pulsed radiofrequency or sham |
| Efficacy of transcutaneous pulsed radiofrequency on hand function | 6 weeks, 12 weeks | Efficacy of trancutaneous pulsed radiofrequency on hand function (Australian/Canadian Hand Osteoarthritis Index \[AUSCAN\] function subscale, range 0-36, with higher scores indicating lower function) |
| Efficacy of transcutaneous pulsed radiofrequency on hand stiffness | 6 weeks, 12 weeks | Efficacy of trancutaneous pulsed radiofrequency on hand stiffness (Australian/Canadian Hand Osteoarthritis Index \[AUSCAN\] stiffness subscale, range 0-4, with higher scores indicating more stiffness) |
| Efficacy of transcutaneous pulsed radiofrequency on the number of tender joints | 6 weeks, 12 weeks | Efficacy of trancutaneous pulsed radiofrequency on the number of tender joints (Tender joint count) |
| Efficacy of trancutaneous pulsed radiofrequency on anxiety | 6 weeks, 12 weeks | Efficacy of trancutaneous pulsed radiofrequency on anxiety measured with the Hospital Anxiety and Depression Scale, anxiety subscale, range 0-21, with higher scores indicating higher likeliness of anxiety, in patients with hand osteoarthritis |
| Efficacy of trancutaneous pulsed radiofrequency on depression | 6 weeks, 12 weeks | Efficacy of trancutaneous pulsed radiofrequency on depression measured with the Hospital Anxiety and Depression Scale, depression subscale, range 0-21, with higher scores indicating higher likeliness of depression, in patients with hand osteoarthritis |
| Global perceived effect of recovery due to trancutaneous pulsed radiofrequency | 6 weeks, 12 weeks | Global perceived effect of recovery due to trancutaneous pulsed radiofrequency, range 0-7, with lower scores indicating better outcomes, reported by patients with hand osteoarthritis |
| Global perceived effect of satisfaction with trancutaneous pulsed radiofrequency | 6 weeks, 12 weeks | Global perceived effect of satisfaction with trancutaneous pulsed radiofrequency, range 0-7, with lower scores indicating better outcomes, reported by patients with hand osteoarthritis |
| Effect of transcutaneous pulsed radiofrequency therapy on health related quality of life | 6 weeks, 12 weeks | Effect of transcutaneous pulsed radiofrequency therapy on health related quality of life measured with Short Form-36. Scores are standardized with a mean of 50 and sd of 10, with higher scores indicating better outcomes |
| Effect of transcutaneous pulsed radiofrequency therapy on temporal summation assessed using a 256 mN PinPrick | 6 weeks | Effect of transcutaneous pulsed radiofrequency therapy on abnormalities measured with temporal summation, scored as present or absent. Patients will receive a single stimulation with the pinprick, scored 0-10 on NRS pain, followed by 10 stimuli with the pinprick, of which the last stimulus is scores 0-10 on NRS pain. This is repeated 5 times. The single stimuli are averaged, as are the 10th stimuli, and the ratio between these averages is calculated. A ratio \>2 is indicative of temporal summation. |
| Effect of transcutaneous pulsed radiofrequency therapy on numbness of the hand. | 6 weeks | Effect of transcutaneous pulsed radiofrequency therapy on numbness scored as present or absent, based on 5 stimuli with the PinPrick. Any stimulus rated as numb is regarded abnormal. |
| Effect of transcutaneous pulsed radiofrequency therapy on allodynia | 6 weeks | Effect of transcutaneous pulsed radiofrequency therapy on allodynia, scored as present or absent. Scoring based on stimuli with a standardized brush, which is used to apply 5 stimuli to the back of the hand. Any of the stimuli evoking pain (score of \>0 on a 0-10 NRS) is regarded as abnormal. |
| Effect of transcutaneous pulsed radiofrequency therapy on PainDETECT scores | 6 weeks, 12 weeks | Effect of transcutaneous pulsed radiofrequency therapy on PainDETECT scores (range -1 to 38, with scores \<13 indicating presence of neuropathic pain is unlikely, scores 13-18 indicating presence of neuropathic pain is undetermined and scores \>18 indicating neuropathic pain presence is likely). |
Other
| Measure | Time frame | Description |
|---|---|---|
| Effect of different QST profiles on tPRF efficacy | 6 weeks, 12 weeks | Effect of different profiles based on quantitative sensory testing on tPRF efficacy in treating pain in hand osteoarthritis. |
| Effect of local inflammation at baseline on the efficacy of tPRF | 6 weeks, 12 weeks | Effect of local inflammation at baseline as measured by ultrasonography based on power doppler signal, effusion and gray scale synovitis, on the efficacy of tPRF in reducing pain in hand osteoarthritis. |
Countries
Netherlands
Contacts
Primary ContactMargreet Kloppenburg, Prof. Dr.
Backup ContactMiranda Van Lunteren, Dr
Outcome results
None listed